Page 32 - pest-POSTEN nr 4, 2018

Cutterguide: No Printing Process: Offset
Size: 168x238 mm Pages: 2 Colors: C M Y K (4 Colors)
Native File: Indesign CS5 Windows Generated in: Acrobat Distiller XI
GD: RV32305
In the management of HIV,
TIMES ARE CHANGING

Are your treatment decisions changing with them?
We are introducing a 2-drug regimen for your virologically suppressed adult HIV patients.

JULUCA (dolutegravir/rilpivirine) is indicated for the treatment of HIV-1 infection in adults
who are virologically suppressed (HIV-1 RNA <50 copies/ml) on a stable antiretroviral regimen
for at least six months with no history of virological failure and no known or suspected
resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.

Contraindications: proton pump inhibitors, dofetilide, rifampicin, rifapentine, carbamazepine,
oxcarbazepine, phenobarbital, phenytoin, systemic dexamethasone, St John’s wort.
Avoid use of Juluca during pregnancy. Women who can be pregnant must use eff ective
contraception. 1

Les preparatomtale før forskrivning. Bivirkninger må rapporteres. Kontakt GSK på telefon 22 70 20 00.

Referanse: 1. EMA Press release 18/05/2018. New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir.
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/05/news_detail_002956. jsp&mid=WC0b01ac058004d5c1
Last accessed 29 May 2018).

JULUCA is owned by or licensed to the ViiV Healthcare group of companies.
©2018 ViiV Healthcare group of companies or its licensor. August 2018: NOR/DTGRPV/0021/18

Juluca_Journ_Ad_168x238mm_2018_NO-9326401_D1.indd 1 8/13/2018 4:17:07 PM